Small-Cap Pharma Stock Reports 120% YoY Growth in Q1 FY27 Profit; Revenue Rises 38%, Secures 65+ Oncology Contracts

On Monday, Indian equity benchmark indices traded higher, with the benchmark Nifty 50 index rising 185.90 points, or 0.78 per cent, to 23,953.35. Amid the positive market sentiment, Sakar Healthcare share price jumped 2.71 per cent to Rs 823.90 after the company reported strong financial results for the quarter ended June 30, 2026, along with significant progress in its oncology business.

Sakar Healthcare Q1 FY27 Financial Performance

Sakar Healthcare reported a robust financial performance for Q1 FY27. Revenue from operations increased 38.39 per cent YoY to Rs 72.97 crore, compared with Rs 52.73 crore in the corresponding quarter last year. EBITDA rose 67.32 per cent YoY to Rs 21.25 crore from Rs 12.70 crore, while the EBITDA margin improved to 29 per cent from 24 per cent.

The company delivered strong profitability during the quarter, with net profit surging 120.13 per cent YoY to Rs 10.28 crore, compared with Rs 4.67 crore in Q1 FY26. The PAT margin expanded to 14 per cent, up from 9 per cent in the year-ago period, supported by operating leverage, improved efficiencies and disciplined cost management.
Also Read - Low PE, High ROCE Auto Major Makes Global Debut in Nepal Through VIDA Brand; Check Details

Oncology Business Continues to Expand

During the quarter, Sakar Healthcare executed more than 65 oncology product contracts, while over 50 additional commercial discussions remain underway, reflecting strong global demand for its oncology portfolio.

The company shared 261 dossiers globally, resulting in 178 regulatory submissions and 16 Marketing Authorisations. It also completed 26 European Marketing Authorisation filings, including 15 owned filings, while securing approvals across multiple European markets.

Sakar Healthcare further strengthened its backward integration by developing 23 oncology APIs in-house, including 16 APIs with Written Confirmation, 2 APIs with CEP approvals, and 5 CEP applications currently under review. In addition, the company is executing 33 technology transfer projects with leading pharmaceutical companies, including Accord-Intas, Torrent, Emcure, Glenmark, and Zydus, of which seven site variation approvals have already been secured across the UK and European Union.

Management Commentary

Commenting on the results, Mr. Sanjay Shah, Managing Director, said: "Q1FY27 marks another period of steady progress, supported by healthy year-on-year growth. The company remains on a strong growth trajectory in terms of both revenue and profitability, reinforcing the promising outlook for the business over the longer term. Our Oncology business remains a key pillar of our strategy. During the quarter, we expanded commercial engagements, strengthened export momentum, and advanced dossier submissions, Marketing Authorizations, site variation approvals, and technology transfer projects with leading global pharmaceutical partners. We also enhanced our integrated oncology platform by expanding our portfolio of in-house APIs supported by key regulatory certifications, reinforcing our capabilities and long-term competitive position.

Looking ahead, we remain confident that converting regulatory approvals into commercial launches and supplies, alongside growing export opportunities and the gradual ramp-up of oncology volumes, will improve capacity utilisation and operating leverage. Backed by a robust product pipeline, regulatory progress, and an expanding international presence, we are well positioned to deliver sustainable and profitable growth. Our long-term outlook remains promising, underpinned by the scalability of our oncology platform and the progressive commercialization of our product portfolio."

About Sakar Healthcare

Established in 2004 and headquartered in Ahmedabad, Gujarat, Sakar Healthcare Limited is a pharmaceutical manufacturer and exporter focused on oncology, antibiotics and general formulations. The company operates EU-GMP and WHO-GMP certified manufacturing facilities for oral solids, injectables, oral liquids and high-potency oncology products.

Sakar Healthcare has a presence in more than 60 countries and provides CDMO, CRAMS and technology transfer services to global pharmaceutical companies. The company continues to strengthen its oncology platform through research and development, regulatory approvals, API integration and sustainable manufacturing practices.

Share your thoughts on Sakar Healthcare's Q1 FY27 performance in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.